Jellagen Pty Ltd completes a new £1.5M equity investment from Angels in Medcity/London Business Angels , Finance Wales and xénos to scale up the manufacture of next generation jellyfish collagen.
Jellagen Pty Ltd, a medical-technology company announces the completion of a further £1,533,000 equity investment led by Angels in Medcity/London Business Angels and Finance Wales with co-investment from xénos, the Wales Business Angel Network and other existing investors.
Jellagen, is exploiting jellyfish to provide the market with a next generation collagen biomaterial that is perceived safer and more technically versatile than current sources of mammalian derived collagen. Collagen is used in the manufacture of biomaterials due to its ability to form strong fibres and used in many forms, including gels scaffolds, and membranes, for a number of medical applications ranging from wound care and soft tissue repair through to bone grafts as collagen is the chief structural protein of the body.
Jellagen’s current range of research grade collagen products are already on market for cell culture application and the business is also conducting in-house development of new medical devices for wound and cartilage repair. The company operates out of the Pembrokeshire Science & Technology Park, Pembroke Dock.